Allergy Therapeutics Seeks Approval for Grass Allergy Treatment

Allergy Therapeutics (GB:AGY) has released an update.

Allergy Therapeutics has submitted a Marketing Authorisation Application to Germany’s Paul Ehrlich Institut for its innovative Grass MATA MPL allergy treatment. This submission marks a crucial step in the regulatory process for the subcutaneous immunotherapy designed to alleviate symptoms of grass pollen allergies. The application is supported by comprehensive data, including a pivotal Phase III trial showcasing significant efficacy over placebo.

For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.